A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- Registration Number
- NCT00002362
- Lead Sponsor
- Triangle Pharmaceuticals
- Brief Summary
This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.
- Detailed Description
Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.
Recruitment & Eligibility
- Status
- SUSPENDED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Ctr for AIDS Research / Education and Service (CARES)
🇺🇸Sacramento, California, United States
San Francisco Veterans Administration Med Ctr
🇺🇸San Francisco, California, United States
Gary Richmond MD
🇺🇸Fort Lauderdale, Florida, United States
Northstar Med Clinic
🇺🇸Chicago, Illinois, United States
South Jersey Infectious Diseases Inc
🇺🇸Somers Point, New Jersey, United States
North Shore Univ Hosp / Div of Infectious Diseases
🇺🇸Manhasset, New York, United States
Univ of Texas Southwestern Med Ctr of Dallas
🇺🇸Dallas, Texas, United States
Houston Clinical Research Network
🇺🇸Houston, Texas, United States
Univ of Texas / Med School at Houston
🇺🇸Houston, Texas, United States
Univ of Texas Health Sciences Ctr
🇺🇸San Antonio, Texas, United States
Ctr for AIDS Research / Education and Service (CARES)🇺🇸Sacramento, California, United States